Home » DDMAC Warns Slate Pharma for Testosterone Drug Ads
DDMAC Warns Slate Pharma for Testosterone Drug Ads
April 16, 2010
The FDA’s Division of Drug Marketing, Advertising and Communications (DDMAC) has cited Slate Pharmaceuticals for marketing claims that promote unapproved
uses of its testosterone drug Testopel, omit and minimize risk information, broaden its indication and overstate its efficacy.